优宁维 (301166)

Shanghai Universal Biotech Co.,Ltd.

ASZ

Tags

ImmunotherapyWeight Loss DrugsSynthetic BiologyBuyback PlansGene ConceptMicro Cap StocksWholesaleBelow IPO PriceMargin Trading and Securities LendingCross-Border E-commerce

K-Line Chart

No K-line data

Stock Details

1. Key Indicators

  • Total Shares(W): 8666.67
  • Circulating A-Shares(W): 5691.87
  • Earnings Per Share(RMB): -0.1700
  • Net Assets Per Share(RMB): 23.3795
  • Operating Revenue(W RMB): 77606.37
  • Total Profit(W RMB): -2402.28
  • Net Profit Attributable to Parent(W RMB): -1507.96
  • Net Profit Growth Rate(%): -207.11
  • Weighted Return on Equity(%): -1.4700
  • Operating Cash Flow Per Share(RMB): -0.4900
  • Undistributed Profit Per Share(RMB): 2.3790
  • Capital Reserve Per Share(RMB): 19.7909

2. Main Business

The main business covers:

  • Providing antibody-centric life science reagents, related instruments, consumables, and comprehensive technical services to universities, research institutes, hospitals, and biopharmaceutical companies.

3. Company Basic Information

  • Company Name: Shanghai Universal Biotech Co., Ltd.
  • Listing Date: 2021-12-28
  • Industry: Wholesale Trade (CSRC Industry)
  • Address: Room 1505, No. 1690 Kongjiang Road, Yangpu District, Shanghai, China
  • Website: www.univ-bio.com
  • Company Profile: On October 28, 2015, Daxin Certified Public Accountants (Special General Partnership) issued the "Audit Report of Shanghai Universal Biotech Co., Ltd." (Daxin Audit No. [2015] 4-00351). As of July 31, 2015, the net assets of Universal Biotech Limited were RMB 52,488,800. On October 30, 2015, Shanghai Shenwei Asset Appraisal Co., Ltd. issued the "Asset and Liability Valuation Report for the Proposed Joint Stock System Reform of Shanghai Universal Biotech Co., Ltd." (Hu Shenwei Ping Bao Zi [2015] No. 0665). As of the valuation base date of July 31, 2015, the net asset valuation of Universal Biotech Limited was RMB 59,966,800. On November 7, 2015, Universal Biotech Limited passed a shareholders' resolution to approve the overall change of the company into a joint stock limited company. Based on the audited net asset value of RMB 52,488,800 as of July 31, 2015, it was converted into 15,000,000 shares of the joint stock limited company at a ratio of 1:0.2858, with the remaining net asset balance credited to capital reserve. On November 23, 2015, the company held its inaugural meeting, and all promoters signed the "Promoters' Agreement." On the same day, Daxin Certified Public Accountants (Special General Partnership) issued the "Capital Verification Report of Shanghai Universal Biotech Co., Ltd." (Daxin Yan Zi [2015] No. 4-00060). As of November 23, 2015, the company had received the share capital of RMB 15,000,000 converted from net assets by all shareholders. On December 8, 2015, the company completed the change registration with the Shanghai Administration for Industry and Commerce. The Unified Social Credit Code is 91310000768354199F.

4. Top 10 Circulating Shareholders

Rank Institution Name Institution Type Shares Held (W) Percentage Held (%)
1 Shanghai Yangzhuo Investment Partnership (Limited Partnership) Legal Person 477.90 8.40
2 Shanghai Chuangye Jieli Taili Venture Investment Center (Limited Partnership) Legal Person 360.37 6.33
3 Noah Multi-Strategy Hybrid Securities Investment Fund Class A Fund 49.91 0.88

5. Concept Sectors

  • Gene Concept
  • Immunotherapy
  • Cross-border E-commerce
  • Weight Loss Drugs
  • Synthetic Biology
  • Margin Trading & Securities Lending
  • Micro-cap Stocks
  • Share Repurchase Plan
  • Below IPO Price

Remarks

  • Data update date: 2026-01-01
  • Data source: Public Market Information